Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for VolitionRX Limited (VNRX : AMEX)
 
 • Company Description   
Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company's development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore.

Number of Employees: 83

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.65 Daily Weekly Monthly
20 Day Moving Average: 82,609 shares
Shares Outstanding: 53.79 (millions)
Market Capitalization: $142.54 (millions)
Beta: 1.65
52 Week High: $4.14
52 Week Low: $2.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.03% 2.97%
12 Week -8.30% -0.51%
Year To Date -15.60% 0.36%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125
-
AUSTIN,TX 78738
USA
ph: 1-646-650-1351
fax: 65 32 8172 5651
investorrelations@volition.com http://www.volition.com
 
 • General Corporate Information   
Officers
Cameron Reynolds - President; Chief Executive Officer and Director
Martin C Faulkes - Chairman
Terig Hughes - Chief Financial Officer and Treasurer
Martin Faulkes - Director
Guy Innes - Director

Peer Information
VolitionRX Limited (CORR.)
VolitionRX Limited (RSPI)
VolitionRX Limited (CGXP)
VolitionRX Limited (BGEN)
VolitionRX Limited (GTBP)
VolitionRX Limited (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 928661107
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 53.79
Most Recent Split Date: (:1)
Beta: 1.65
Market Capitalization: $142.54 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.54 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 13.19
Price/Cash Flow: -
Price / Sales: 796.33
EPS Growth
vs. Year Ago Period: -16.67%
vs. Previous Quarter: 6.67%
Sales Growth
vs. Year Ago Period: 338.46%
vs. Previous Quarter: 714.29%
ROE
03/31/22 - -148.44
12/31/21 - -110.92
09/30/21 - -100.42
ROA
03/31/22 - -91.08
12/31/21 - -80.49
09/30/21 - -72.52
Current Ratio
03/31/22 - 1.48
12/31/21 - 3.37
09/30/21 - 4.17
Quick Ratio
03/31/22 - 1.48
12/31/21 - 3.37
09/30/21 - 4.17
Operating Margin
03/31/22 - -15,827.93
12/31/21 - -29,465.93
09/30/21 - -28,471.43
Net Margin
03/31/22 - -15,827.93
12/31/21 - -29,465.93
09/30/21 - -28,471.43
Pre-Tax Margin
03/31/22 - -15,967.59
12/31/21 - -29,977.23
09/30/21 - -28,621.43
Book Value
03/31/22 - 0.20
12/31/21 - 0.33
09/30/21 - 0.40
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.23
12/31/21 - 0.16
09/30/21 - 0.12
Debt-to-Capital
03/31/22 - 18.90
12/31/21 - 13.57
09/30/21 - 10.78
 

Powered by Zacks Investment Research ©